3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
3
Thoracic
2
Sarcoma
2
Endocrine
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
14
Neoplasms
5
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Uveal Melanoma
2
Thyroid Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Skin Diseases
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Interventions
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Biliary Tract Neoplasms
×
Dermatologic
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA